Cardiovascular Events in Cancer Patients Receiving Highly Emetogenic or Moderately Emetogenic Chemotherapy
Patients were not recruited for nor enrolled in this study. This study is a retrospective
observational study. Data from medical records or insurance claims databases are anonymised
and used to develop a patient cohort. All diagnoses and treatment are recorded in the
course of routine medical practice.
- Enrollment in IHCIS in 2006
- At least one HEC or MEC claim in 2006
- HEC or MEC claim three months before first HEC/MEC claim - "wash-in" period (i.e.
must be enrolled for three months prior to first HEC/MEC claim. For patients whose
first HEC/MEC event is between January 1,2006 and March 31, 2006, enrollment criteria
for inclusion in the study may extend as far back as October 1, 2005)
- HEC or MEC claims prior to 45 days after last HEC or MEC claim - "wash-out" period.
(For patients whose last claim in 2006 was seen after December 1, 2006 enrollment
into 2007 to look for further treatment and the 45 day "wash-out" period will be
Type of Study:
Observational Model: Cohort, Time Perspective: Retrospective
Calculate the frequency and percent of patients with selected cardiovascular and arterial thromboembolic events in the analysis period, stratifying by any use of aprepitant (Emend) during the analysis period.
Outcome Time Frame:
First day of first HEC/MEC cycle to 30 days past first day of last cycle
United States: No Health Authority
- Cardiovascular Event
- Arterial Thromboembolic Event
- highly emetogenic chemotherapy
- moderately emetogenic chemotherapy